+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Urate-stimulating Excretion Agents Market - Global Forecast 2026-2032- Product Image
Urate-stimulating Excretion Agents Market - Global Forecast 2026-2032- Product Image
Sale

Urate-stimulating Excretion Agents Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6147908
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Urate-stimulating Excretion Agents Market is projected to reach USD 1.40 Billion in 2026. It is expected to continue growing at a CAGR of 8.65%, reaching USD 2.31 Billion by 2032.

Urate-Stimulating Excretion Agents: Executive Overview

Urate-stimulating excretion agents are therapies intended to increase urinary uric acid elimination and support management of hyperuricemia and gout. Their clinical value is shaped by renal function, treatment adherence, drug interactions, disease severity, and the need to balance urate reduction with safety monitoring. The market is therefore influenced by evolving clinical guidance, diagnostic practices, patient access, and the broader shift toward individualized chronic-disease management.

Clinical Practice Is Shifting Toward Risk-Based, Long-Term Management

Treatment is increasingly organized around sustained urate control rather than episodic relief of acute symptoms. Clinicians are placing greater emphasis on treat-to-target approaches, renal and cardiovascular risk assessment, medication review, patient education, and monitoring of adherence. These shifts create demand for therapies that can be incorporated into durable treatment pathways while addressing contraindications, tolerability concerns, and differences in patient response.

Artificial Intelligence Is Improving Identification, Monitoring, and Personalization

Artificial intelligence can support this field by identifying patients at risk of uncontrolled hyperuricemia, integrating laboratory and clinical records, and helping clinicians recognize patterns associated with treatment response or adverse events. Predictive tools may also assist adherence interventions and prioritize follow-up. However, meaningful clinical use requires representative data, transparent validation, privacy safeguards, and human oversight, particularly where recommendations affect renal safety or medication selection.

Regional Insights: Access and Care Pathways Vary Widely

North America is characterized by broad clinical infrastructure, electronic health-record adoption, and attention to comorbid kidney and cardiovascular disease. Europe combines structured guideline-based care with differing reimbursement and national formulary practices. Asia-Pacific includes diverse disease burdens, healthcare systems, and urbanization patterns, with Japan, China, India, South Korea, and Australia reflecting distinct regulatory and clinical environments. Latin America faces uneven specialist access and affordability constraints, while the Middle East is shaped by metabolic-risk burdens and concentrated healthcare capacity. Africa presents substantial opportunities for earlier diagnosis and improved continuity of care, alongside challenges involving laboratory access, supply reliability, and workforce capacity.

Group Insights: Economic and Regulatory Blocs Shape Implementation

ASEAN markets require adaptable access strategies because regulatory processes, reimbursement structures, and healthcare capacity differ across member states. BRICS countries combine large and varied patient populations with distinct procurement and domestic-manufacturing priorities. The European Union benefits from shared regulatory principles but retains national differences in reimbursement and clinical implementation. G7 systems generally have stronger diagnostic infrastructure and pharmacovigilance capabilities, although cost-effectiveness and aging populations remain important considerations. GCC countries often have centralized purchasing and advanced urban care networks, while NATO members span diverse health systems and policy priorities, making country-level execution essential.

Country Insights: Local Disease Profiles and Health Systems Drive Adoption

Australia and Canada emphasize guideline-led care across geographically dispersed populations. Brazil and Mexico must address uneven access, affordability, and specialist distribution. China and India combine substantial patient needs with rapidly evolving urban healthcare, diagnostic, and pharmaceutical ecosystems. France, Germany, Italy, Spain, and the United Kingdom operate within mature European systems where reimbursement, prescribing pathways, and national guidance influence uptake. Japan and South Korea have sophisticated clinical and regulatory environments with strong attention to aging-related disease management. Russia’s implementation is affected by healthcare access, procurement, and regulatory conditions. The United States combines extensive clinical capacity with complex coverage, pharmacy, and care-coordination requirements.

Industry Priorities: Strengthen Safety, Access, and Real-World Evidence

Leaders should develop therapies and services around renal safety, interaction management, clear dosing guidance, and practical adherence support. Partnerships with clinicians and healthcare systems can improve patient identification, laboratory monitoring, and continuity of care. Evidence programs should assess outcomes across comorbidities, age groups, renal-function categories, and diverse populations. Access strategies should be tailored to national reimbursement and procurement conditions rather than applied uniformly. Digital tools, including artificial-intelligence applications, should be introduced with validated clinical endpoints, explainability, cybersecurity, and explicit clinician accountability.

Research Methodology: Evidence Synthesis Across Clinical and Health-System Dimensions

This executive summary uses the defined market scope of urate-stimulating excretion agents and organizes analysis around clinical practice, regulation, access, technology, and geography. Insights are derived from established principles of hyperuricemia and gout management, health-system variation, and the operational implications of renal monitoring and chronic adherence. Regional, group, and country perspectives are presented qualitatively, without market estimates, forecasts, shares, or company-specific claims. Interpretation should be supplemented with current clinical guidelines, regulatory decisions, reimbursement policies, safety communications, and peer-reviewed evidence.

Conclusion: Sustainable Value Depends on Integrated, Patient-Centered Care

The trajectory of urate-stimulating excretion agents will depend less on pharmacologic action alone than on how effectively therapies are integrated into diagnosis, monitoring, adherence support, and long-term risk management. Regional and country differences require locally appropriate access and implementation models. Leaders that combine robust safety evidence, responsible data use, practical care pathways, and equitable patient support will be better positioned to address the clinical complexity of hyperuricemia and gout.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Urate-stimulating Excretion Agents Market, by Product Type
7.1. Introduction
7.2. Benzbromarone
7.3. Lesinurad
7.4. Probenecid
7.5. Sulfinpyrazone
8. Urate-stimulating Excretion Agents Market, by Dosage Form
8.1. Introduction
8.2. Capsules
8.3. Oral Suspension
8.4. Powder
8.5. Tablets
9. Urate-stimulating Excretion Agents Market, by Route Of Administration
9.1. Introduction
9.2. Oral
10. Urate-stimulating Excretion Agents Market, by Application
10.1. Introduction
10.2. Gout
10.3. Hyperuricemia
10.4. Lesch-Nyhan Syndrome
11. Urate-stimulating Excretion Agents Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Urate-stimulating Excretion Agents Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Healthcare
12.4. Hospitals
13. Urate-stimulating Excretion Agents Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Urate-stimulating Excretion Agents Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Urate-stimulating Excretion Agents Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AstraZeneca Plc
17.2. Dr. Reddy's Laboratories Ltd.
17.3. Fuji Yakuhin Co., Ltd.
17.4. Hikma Pharmaceuticals PLC
17.5. Lannett Company, Inc.
17.6. Novartis AG
17.7. Pfizer Inc.
17.8. Sanofi
17.9. Teva Pharmaceutical Industries Ltd.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Urate-stimulating Excretion Agents Market, Years Considered for the Study
FIGURE 2. Global Urate-stimulating Excretion Agents Market, Research Design
FIGURE 3. Global Urate-stimulating Excretion Agents Market, Research Framework
FIGURE 4. Global Urate-stimulating Excretion Agents Market, Data Triangulation
FIGURE 5. Global Urate-stimulating Excretion Agents Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Urate-stimulating Excretion Agents Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Urate-stimulating Excretion Agents Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 9. Global Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Urate-stimulating Excretion Agents Market Size, by Application, 2025 vs 2032 (%)
FIGURE 13. Global Urate-stimulating Excretion Agents Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Urate-stimulating Excretion Agents Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global Urate-stimulating Excretion Agents Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Urate-stimulating Excretion Agents Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Urate-stimulating Excretion Agents Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Urate-stimulating Excretion Agents Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Urate-stimulating Excretion Agents Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Urate-stimulating Excretion Agents Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Urate-stimulating Excretion Agents Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Urate-stimulating Excretion Agents Market Segmentation & Coverage
TABLE 2. Global Urate-stimulating Excretion Agents Market Size, 2017-2032 (USD Million)
TABLE 3. Global Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Benzbromarone Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Benzbromarone Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Benzbromarone Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Lesinurad Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Lesinurad Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Lesinurad Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Probenecid Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Probenecid Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Probenecid Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Sulfinpyrazone Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Sulfinpyrazone Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Sulfinpyrazone Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 17. Global Capsules Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Capsules Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Capsules Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Oral Suspension Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Oral Suspension Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Oral Suspension Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Powder Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Powder Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Powder Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 30. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 34. Global Gout Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Gout Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Gout Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Hyperuricemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Hyperuricemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Hyperuricemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Lesch-Nyhan Syndrome Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Lesch-Nyhan Syndrome Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Lesch-Nyhan Syndrome Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 44. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 54. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Home Healthcare Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Home Healthcare Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Home Healthcare Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Urate-stimulating Excretion Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific Urate-stimulating Excretion Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 71. North America Urate-stimulating Excretion Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. North America Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 73. North America Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 74. North America Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 75. North America Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 76. North America Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 77. North America Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 78. Latin America Urate-stimulating Excretion Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Latin America Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 80. Latin America Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 81. Latin America Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 82. Latin America Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 83. Latin America Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 84. Latin America Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 85. Europe Urate-stimulating Excretion Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Europe Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 87. Europe Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 88. Europe Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 89. Europe Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 90. Europe Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 91. Europe Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 92. Middle East Urate-stimulating Excretion Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Middle East Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 94. Middle East Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 95. Middle East Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 96. Middle East Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 97. Middle East Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 98. Middle East Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 99. Africa Urate-stimulating Excretion Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Africa Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 101. Africa Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 102. Africa Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 103. Africa Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 104. Africa Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 105. Africa Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 106. Global Urate-stimulating Excretion Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. ASEAN Urate-stimulating Excretion Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. ASEAN Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 109. ASEAN Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 110. ASEAN Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 111. ASEAN Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 112. ASEAN Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 113. ASEAN Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. GCC Urate-stimulating Excretion Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. GCC Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 116. GCC Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 117. GCC Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 118. GCC Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 119. GCC Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 120. GCC Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 121. European Union Urate-stimulating Excretion Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 122. European Union Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 123. European Union Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 124. European Union Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 125. European Union Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 126. European Union Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 127. European Union Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 128. BRICS Urate-stimulating Excretion Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. BRICS Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 130. BRICS Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 131. BRICS Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 132. BRICS Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 133. BRICS Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 134. BRICS Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. G7 Urate-stimulating Excretion Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. G7 Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 137. G7 Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 138. G7 Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 139. G7 Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 140. G7 Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 141. G7 Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 142. NATO Urate-stimulating Excretion Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. NATO Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 144. NATO Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 145. NATO Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 146. NATO Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 147. NATO Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 148. NATO Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 149. Global Urate-stimulating Excretion Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 150. United States Urate-stimulating Excretion Agents Market Size, 2017-2032 (USD Million)
TABLE 151. United States Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 152. United States Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 153. United States Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 154. United States Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 155. United States Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 156. United States Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 157. Canada Urate-stimulating Excretion Agents Market Size, 2017-2032 (USD Million)
TABLE 158. Canada Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 159. Canada Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 160. Canada Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 161. Canada Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 162. Canada Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 163. Canada Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 164. Mexico Urate-stimulating Excretion Agents Market Size, 2017-2032 (USD Million)
TABLE 165. Mexico Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 166. Mexico Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 167. Mexico Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 168. Mexico Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 169. Mexico Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 170. Mexico Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 171. Brazil Urate-stimulating Excretion Agents Market Size, 2017-2032 (USD Million)
TABLE 172. Brazil Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 173. Brazil Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 174. Brazil Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 175. Brazil Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 176. Brazil Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 177. Brazil Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 178. United Kingdom Urate-stimulating Excretion Agents Market Size, 2017-2032 (USD Million)
TABLE 179. United Kingdom Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 180. United Kingdom Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 181. United Kingdom Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 182. United Kingdom Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 183. United Kingdom Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 184. United Kingdom Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. Germany Urate-stimulating Excretion Agents Market Size, 2017-2032 (USD Million)
TABLE 186. Germany Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 187. Germany Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 188. Germany Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 189. Germany Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 190. Germany Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 191. Germany Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 192. France Urate-stimulating Excretion Agents Market Size, 2017-2032 (USD Million)
TABLE 193. France Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 194. France Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 195. France Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 196. France Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 197. France Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 198. France Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. Russia Urate-stimulating Excretion Agents Market Size, 2017-2032 (USD Million)
TABLE 200. Russia Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 201. Russia Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 202. Russia Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 203. Russia Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 204. Russia Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 205. Russia Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 206. Italy Urate-stimulating Excretion Agents Market Size, 2017-2032 (USD Million)
TABLE 207. Italy Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 208. Italy Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 209. Italy Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 210. Italy Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 211. Italy Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 212. Italy Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 213. Spain Urate-stimulating Excretion Agents Market Size, 2017-2032 (USD Million)
TABLE 214. Spain Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 215. Spain Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 216. Spain Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 217. Spain Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 218. Spain Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 219. Spain Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 220. China Urate-stimulating Excretion Agents Market Size, 2017-2032 (USD Million)
TABLE 221. China Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 222. China Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 223. China Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 224. China Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 225. China Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 226. China Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 227. India Urate-stimulating Excretion Agents Market Size, 2017-2032 (USD Million)
TABLE 228. India Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 229. India Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 230. India Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 231. India Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 232. India Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 233. India Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 234. Japan Urate-stimulating Excretion Agents Market Size, 2017-2032 (USD Million)
TABLE 235. Japan Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 236. Japan Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 237. Japan Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 238. Japan Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 239. Japan Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 240. Japan Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 241. Australia Urate-stimulating Excretion Agents Market Size, 2017-2032 (USD Million)
TABLE 242. Australia Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 243. Australia Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 244. Australia Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 245. Australia Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 246. Australia Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 247. Australia Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 248. South Korea Urate-stimulating Excretion Agents Market Size, 2017-2032 (USD Million)
TABLE 249. South Korea Urate-stimulating Excretion Agents Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 250. South Korea Urate-stimulating Excretion Agents Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 251. South Korea Urate-stimulating Excretion Agents Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 252. South Korea Urate-stimulating Excretion Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 253. South Korea Urate-stimulating Excretion Agents Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 254. South Korea Urate-stimulating Excretion Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 255. Global Urate-stimulating Excretion Agents Market Share, by Key Player, 2025
TABLE 256. Global Urate-stimulating Excretion Agents Market, Key Experts

Companies Mentioned

  • AstraZeneca Plc
  • Dr. Reddy's Laboratories Ltd.
  • Fuji Yakuhin Co., Ltd.
  • Hikma Pharmaceuticals PLC
  • Lannett Company, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

Related Topics

Related Reports

Chronic Gout - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Chronic Gout - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Gout Therapeutics Market - Global Forecast 2026-2032 - Product Image

Gout Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Gout Therapeutics Market - Forecast from 2026 to 2031 - Product Image

Gout Therapeutics Market - Forecast from 2026 to 2031

  • Report
  • 151 Pages
  • Global
From
Gout Therapeutics - Global Strategic Business Report - Product Image

Gout Therapeutics - Global Strategic Business Report

  • Report
  • 279 Pages
  • Global
From
Drugs for the Treatment of Refractory Gout Market - Global Forecast 2026-2032 - Product Image

Drugs for the Treatment of Refractory Gout Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.